Filters Resource type Area of interest Brochures & Flyers Organ-on-a-chip Contract Research Services Brochure Discover our full range of Organ-on-a-chip contract research services including ADME, NASH, DILI and Oncology as well as all the relevant endpoints. Blogs Immune-mediated DILI – Predicting the unpredictable! Dr Anthony Berger discusses the limitations of the existing workflow and how organ-on-a-chip can help to predict the unpredictable, immune-mediated DILI. Scientific publications Normalization of organ-on-a-Chip samples for mass spectrometry based proteomics and metabolomics via Dansylation-based assay Gallagher et al., 2022 This study shows the importance of normalization for paired MS-based multi-omics-OOC studies to accurately investigate highly toxic hazards and their effects on the human liver. Using VX, a highly toxic chemical compound, the study identifies VX-specific toxic effects on 3D liver tissues as well as specific hepatic cellular biomarkers and pathways affected by the toxic agent. Application notes Human liver microphysiological system for predicting the drug-induced liver toxicity of differing drug modalities Novac et al The liver is one of the organs most susceptible to drug toxicity and drug-induced liver injury (DILI). With more than 750 FDA-approved drugs known to have a degree of DILI risk, better preclinical models are required to de-risk new therapeutics earlier in the drug development process. We assess whether a Liver MPS model could be used to understand the detailed mechanistic aspects of liver toxicity. Application notes Microphysiological system for studying fatty liver disease and its impact on drug-induced liver injury Kostrzewski et al As a result of the increased prevalence of diabetes, obesity, and metabolic syndrome, non-alcoholic fatty liver disease (NAFLD) is now the most common chronic liver disease in developed countries. Using better in vitro models to fast-track therapeutic development but also accurately assess DILI risk in NASH patients ahead of the clinic is critical. Here, we show the potential of an in vitro 3D NASH model to accurately identify any DILI-associated risks. Posters Assessing drug-induced liver injury using a sensitive and selective human liver microphysiological system and clinical biomarkers Novac et al Drug-induced liver injury (DILI) is the most common cause of acute liver failure and a leading cause of compound attrition in drug development. In this poster, we demonstrate the potential of a liver MPS to better predict toxicity and improve in vitro to in vivo translation. Scientific publications Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro Novac et al., 2022 This study demonstrates the capability of a human liver MPS to generate clinically-relevant, high-content data (six endpoint EC50 curves). A broad set of known severely and mildly hepatotoxic compounds to accurately predict human DILI and its mechanism versus conventional approaches. Scientific publications Multiorgan microphysiological systems as tools to interrogate interorgan crosstalk and complex diseases Trapecar, 2022 A review of the state of multi-organ microphysiological systems in 2021. Overviews of currently available multi-organ MPS and the different technologies, cells and physiological cues used. Discusses approaches for systems biology integration and how MPS can be more readily adopted in the wider research community. Blogs De-risking drug-induced liver injury through the predictive power of organ-on-a-chip Unfortunately, it is not uncommon that DILI (Drug-induced liver injury) is only first identified in the clinic. Find out how our systems can help you identify it in your lab. Webinars Fighting Toxic Chemicals: Evaluating the Safety of Cobinamide as a Neutralizing Agent Webinar Series 4 Episode 3: This webinar outlines how Boss’ lab used CN Bio’s DILI Services to investigate the hepatotoxicity of two cobinamide formulations. Webinars Predictive DILI Models: Human Liver Microphysiological System for Studying Acute and Chronic Drug-Induced Liver Toxicity Webinar Series 4 Episode 2: In this webinar, CN Bio Senior Scientist Dr. Ovidiu Novac discusses how a human liver microphysiological system (MPS), or Liver-on-a-chip, can be used to understand the causality and mechanistic aspects of drug-induced liver injury (DILI). Scientific publications Characterizing the reproducibility in using a liver microphysiological system for assaying drug toxicity, metabolism and accumulation Rubiano et al., 2020 This study demonstrated the ability of the CN Bio’s PhysioMimix liver model to generate reproducible results from experiments assaying metabolism, drug toxicity and intracellular accumulation. The results from the paper showed that the liver MPS can be routinely used in general drug evaluation applications.